Samsung Epis Holdings Co., Ltd. 0126Z0
KRX · South Korea · Health Technology
KRW 373,500.00+27,500.00 (+7.95%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
INCHEON, Korea & TEL AVIV, Israel, October 01, 2026--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab).
INCHEON, Korea, July 24, 2026--Samsung Epis Holdings announced its financial results for the second quarter and first half of fiscal year 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.